N/A
N=5
Memory and Attention Adaptation Training-Geriatrics (MAAT-G)
Cancer-related Problem/Condition · Cognitive Impairment
Bottom Line
View on ClinicalTrials.gov: NCT04230941 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
Jul 2023
Primary outcome: Primary: System Usability Scale (SUS) — 90.6 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- MAAT-G (Behavioral)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- University of Rochester
- Primary completion
- Apr 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY System Usability Scale (SUS) |
90.6 | — |
| PRIMARY Experience Interview |
4; 1; 3; 1 | — |
Summary
Cancer-related cognitive dysfunction (CRCD) affects up to 75% of patients receiving chemotherapy and older adults are at greater risk of developing CRCD, which can negatively affect their functional independence and quality of life. Memory and Attention Adaptation Training (MAAT) is a promising treatment for CRCD that improves perceived cognition in younger cancer survivors, but needs to be adapted for older adults to address their unique needs. The proposed study will adapt MAAT for older adults using feedback from key stakeholders (older adults with cancer and their caregivers), and test usability of the intervention.
Eligibility Criteria
Patient Inclusion Criteria:
- Have a diagnosis of invasive breast cancer
- Planned to receive systemic therapy for breast cancer or actively receiving systemic therapy for breast cancer with two additional cycles remaining.
- Be age 65 or older
- Able to provide informed consent
- Able to read and understand English (or possess a designated health care proxy that can do the same that was designated prior to the patient losing decision-making capabilities)
Patient Exclusion Criteria:
- Have surgery planned within 3 months of consent
- Patients who do not have decision-making capacity (decisionally or cognitively impaired) AND do NOT have a previously designated health care proxy (established prior to their cognitive impairment) available to sign consent
- Patients with breast cancer receiving endocrine therapy as their only systemic therapy will not be eligible.
Eligible Caregiver Inclusion Criteria:
- Selected by the patient when asked if there is a "family member, partner, friend or caregiver [age 21 or older] with whom you discuss or who can be helpful in health-related matters;" patients who cannot identify such a person ("caregiver") will remain eligible for the study.
Eligible Caregiver Exclusion Criteria:
- Caregivers unable to understand the consent form due to cognitive, health or sensory impairment will be excluded
Data sourced from ClinicalTrials.gov (NCT04230941). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.